Year in Review: Multiple Myeloma

Center on Health Equity & Access
Clinical
Health Care Cost
Health Care Delivery
Insurance
Policy
Technology
Value-Based Care

Biosimilars Cardiorenalmetabolic Dermatology Gastroenterology Hematology Hepatology Immunology Infectious Disease MASH Mental Health Neurology Obesity Oncology Ophthalmology Pulmonology Rare Disease Respiratory Rheumatology Women's Health

Free In-Person Regional Events Focused on Oncology and Population Health

Biosimilars Center on Health Equity & Access Digital Health Formulary Gene Therapy Guidelines Health Care Administration Health Care Cost Health Care Delivery Insurance Policy Population Health Product Approvals and Launches Technology Value-Based Care

All Coverage Event Coverage Interviews News

AJMC Journals Anniversary Author Forms Authors Nominate a Rising Leader Submit a Manuscript

Year in Review: Multiple Myeloma

December 18, 2024

Publication

Article

Supplements and Featured PublicationsYear in Review: Multiple Myeloma

This 2024 multiple myeloma year in review recaps clinical trial data presented at major conferences and important FDA updates, including the April 2024 vote by the Oncologic Drug Advisory Committee that measures of minimal residual disease (MRD) negativity could be part of a surrogate end point in trials.

Year in Review: Multiple Myeloma

Do Not Sell My Information

Terms & Conditions

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777